Introduction 

Cerebrotendinous xanthomatosis (CTX) is a very rare, autosomal recessive metabolic condition of bile acid biosynthesis due to CYP27A1 gene mutations encoding for sterol 27‑hydroxylase (an enzyme necessary for the conversion of cholesterol to bile acids). The subsequent deficiency affects the alternative pathway of bile acid synthesis, heavily compromising metabolism. This results in cholestanol and bile alcohol accumulation in lipid-bearing tissues, such as the central nervous system (CNS) and tendons, with a characteristic clinical picture.^1,2,3

Clinically, CTX is distinguished by a broad and frequently confusing array of symptoms. Early manifestations show up as infantile‑onset diarrhoea and juvenile‑onset cataracts, whereas tendon xanthomas, an increasingly disabling neurological dysfunction, appears subsequently in the form of ataxia, dementia, psychiatric illness, and seizures. The mean age of symptomatic onset is about 19 years, but definitive diagnosis is given at the age of 35, with over 10 years of diagnostic delay. This lacuna highlights the need for the identification of hallmark features such as cholestanol deposition in the CNS and tendons.^1,4,5

The early detection and initiation of treatment with chenodeoxycholic acid (CDCA) can significantly modify this disease course by normalising sterol metabolism and arresting or reversing disease progression. This article outlines mechanisms of cholestanol deposition in tendons and the brain, their implications for clinical practice, diagnostic strategies, treatment plans, and overall prognosis of CTX, based on peer-review evidence for all the discussion.^1,6

Pathophysiology of cerebrotendinous xanthomatosis

Genetic cause

CTX is caused by homozygous or compound heterozygous CYP27A1 mutations leading to sterol 27‑hydroxylase dysfunction or deficiency. More than 100 pathogenic variants have been described in various populations.^1,7

Biochemical consequences

The sterol 27-hydroxylase deficiency disrupts the conversion of cholesterol to primary bile acids (i.e., cholic acid and CDCA). It inhibits the alternative pathway of bile acid synthesis and encourages accumulation of precursors like 7α-hydroxy-4-cholesten-3-one, which get shunted instead into non-physiological metabolites—cholestanol and bile alcohols—that accumulate systemically.^2,8,9,10

Target tissues

Selective deposits of cholestanol appear in the CNS (white matter, cortical, and subcortical structures including the cerebellum), tendons, the achilles, patellar, and other extensors. Other sites of deposit are the eye lens (causing cataracts), bones (osteoporosis), arteries, and lungs.^1,9,10

Cholestanol accumulation in the brain 

Mechanism of CNS involvement

The processes by which cholestanol is deposited in the brain tissue are not yet fully understood, but are related to defective feedback regulation of bile acid synthesis and pathologic excess production of cholestanol, that gains entry to CNS tissues, presumably via pathologic metabolism of the blood-brain barrier.^1,10

Neurological manifestations

The patient increasingly develops a variety of neurological deficits, including:

• Cerebellar ataxia, which is a frequent initial feature
• Dementia and cognitive impairment
• Seizures, sometimes preceded by other presentations
• Psychiatric presentation of depression, agitation, and hallucination
• Peripheral neuropathy with the following signs: muscle atrophy and pes cavus^10,11,12

Neuroimaging findings

Brain MRI typically shows:

• Cerebellar and cerebral atrophy
• Hyperintense signals for white matter and dentate nuclei on T2/FLAIR images
• Spinal cord atrophy in advanced cases

These imaging findings confirm the clinical suspicion, particularly in the presence of tendon xanthomas or early cataracts.^1,10

Cholestanol accumulation in the tendons 

Tendon xanthomas

Tendon xanthomas are painless, hard, slowly enlarging nodules that most frequently occur on the achilles tendons in late adolescence or early adulthood, and subsequently affects patellar and extensor tendons.^1,11 These are usually the first palpable physical manifestations of CTX.

Histopathological examination of tendon lesions shows foamy histiocytes, cholesterol clefts, and multinucleated giant cells in a fibrous stroma. Fusiform swelling of the tendon with lipid infiltration on MRI or ultrasound is distinguishable from other mass lesions.^12,13

Clinical relevance

Tendon xanthomas are the most traditional and one of the first presentations of CTX, it can also antedate neurological symptoms. This condition should be monitored, particularly in the setting of normal serum lipid panels, a distinguishing feature from familial hypercholesterolemia or sitosterolemia. Physicians should be aware of other related signs, such as juvenile cataracts or chronic diarrhoea for early diagnosis.^9,11

Prognosis and importance of early detection

The prognosis of cerebrotendinous xanthomatosis (CTX) is profoundly influenced by the timing of diagnosis and intervention. The central pathological feature of CTX, the progressive accumulation of cholestanol in the brain and tendons, leads to irreversible structural and functional damage if not identified and treated in a timely manner. Neurological manifestations, including cognitive decline, cerebellar ataxia, seizures, and psychiatric disturbances, are directly related to cholestanol-induced degeneration of cerebral and cerebellar tissues. Similarly, tendon xanthomas, particularly in the achilles and patellar tendons, result from chronic lipid infiltration, leading to mechanical and cosmetic complications.^1,11

Unfortunately, CTX remains underdiagnosed and frequently misdiagnosed, with an average diagnostic delay of 10-20 years from the onset of initial symptoms. This delay is largely due to the nonspecific and multisystemic nature of early signs, which may include chronic diarrhoea, juvenile cataracts, and mild developmental delays. By the time tendon xanthomas or prominent neurological symptoms arise which are hallmarks of advanced cholestanol accumulation, significant and often irreversible tissue damage may have already occurred.¹²

Early identification of CTX is therefore critical. Clinicians should be alerted by the presence of any combination of the following symptoms:

• Juvenile cataracts
• Chronic diarrhoea in infancy or childhood
• Development of tendon xanthomas in adolescence
• Progressive neurological deficits
• Compatible MRI findings (e.g., cerebellar atrophy, white matter changes)

A structured clinical suspicion index that incorporates these signs has been proposed and shown to aid in earlier diagnostic consideration. Additionally, newborn screening methods targeting specific bile alcohol metabolites or cholestanol precursors in dried blood spots are under investigation and show potential in enabling pre-symptomatic detection.¹³

Diagnosis of CTX 

Clinical clues

The diagnosis relies upon a composite clinical profile which includes: infantile diarrhoea, juvenile cataracts, tendon xanthomas, and neurological deterioration. Also, consanguinity or family history raises chance.^1,11

Laboratory tests

The main diagnostic markers of cerebrotendinous xanthomatosis (CTX) include: raised plasma cholestanol and raised urinary bile alcohols. More sensitive tests may include abnormal bile acid precursors.^1,10

Genetic testing & imaging

This condition can be confirmed through the identification of CYP27A1 mutations by genetic testing. There are more supportive evidence of anatomical involvement from neuroimaging (brain MRI) and tendon imaging (MRI or ultrasound).^1,12

Surprisingly, neonatal dried blood spot for metabolic biomarkers is being researched and it might possibly enable early recognition and treatment.^9,10

Treatment and management

Chenodeoxycholic acid (CDCA) replacement

Chenodeoxycholic acid (CDCA) supplements work by lowering bile acid levels, re-establishing feedback inhibition of cholesterol metabolism, and shortening the synthesis of cholestanol. This experience dates back to the 1970s, with benefits demonstrated over decades. Some benefits include:

• Normalisation of plasma/CSF cholestanol concentration
• Stabilisation or reversal of neurological deterioration
• Regression or stabilisation of xanthomas and systemic manifestations^1,9,11

Supportive therapies

Adjunct therapies include: HMG-CoA reductase inhibitors (statins) to further decrease cholestanol production. Symptom-guided management options include: cataract extraction, rehabilitation therapies, antiepileptics, psychiatric and movement disorder support.^10,11 

Prognosis

The outcome of CTX is extremely time-sensitive. Those receiving early treatment, before vast neurological damage occurs, can attain significant improvement. However, delayed diagnosis always results in irreversible injury to the CNS even with appropriate management.^1,11

FAQs

What is CTX and what causes it?

CTX is an autosomal recessive rare disease caused by mutations in CYP27A1, affecting bile acid production and cholestanol deposition in all tissues.

Why do patients develop tendon xanthomas?

Cholestanol deposits in tendon tissue leads to xanthoma formation which are fatty, painless nodules, commonly found on the achilles and tendons.

Why is neurological damage so prominent?

Cholestanol penetrates the CNS, damaging neurons and causing demyelination, thereby leading to ataxia, mental regression, seizures, and psychiatric symptoms.

How is CTX diagnosed?

Diagnosis integrates clinical presentation (e.g., xanthomas, cataract) through plasma cholestanol elevation, genetic confirmation of CYP27A1 mutations, and supportive MRI findings.

What is the treatment?

Oral CDCA therapy is the first line of treatment, it normalises bile acid, corrects cholestanol, and prevents progression. Statins and symptomatic management also add to the treatment.

Why is early diagnosis critical?

Treatment is much more successful when it starts before irreversible neurological damage; delay usually leads to permanent disability.

Can newborn screening help?

New dried blood spot newborn screening tests using biomarker-based tests have been promising in early diagnosis of CTX and thus potentially allows pre-symptomatic intervention. 

Summary

All in all, deposition of cholestanol within the brain and tendons constitutes the characteristic sign of cerebrotendinous xanthomatosis (CTX). The pathophysiology of the disease, its basis in CYP27A1 mutations interfering with bile acid production results in cholestanol's aberrant deposition within lipophilic tissues to cause neurodegeneration and tendon xanthomas. Identification of these characteristic signs particularly in combination with ocular and gastrointestinal symptoms is pivotal to diagnosis.

Diagnosis is based on a blend of clinical presentation, raised biochemical tests (plasma cholestanol, urinary bile alcohols), genetic testing, and diagnostic imaging. Chenodeoxycholic acid (CDCA) treatment is particularly effective if begun early, which may prevent or reverse the disease. CDCA's recent FDA approval (Ctexli) is a mega step in adult CTX therapy.

With the catastrophic outcome of delayed treatment, usually ending in permanent neurologic disability, a serious, multi-disciplinary effort is called for. Heightened awareness by paediatricians, neurologists, ophthalmologists, and metabolic specialists, coupled with new screening technologies, can make a revolutionary difference in outcomes in this rare but treatable disease.